|Address:||The Jenner Institute, Old Road Campus Research Building Roosevelt Drive, Oxford, OX3 7DQ|
|Tel:||+44 (0)1865 617637|
|Principal areas of research:||Prostate cancer vaccines|
I studied biology at the Third University of Rome and obtained my PhD degree from the University of Duisburg-Essen in the summer of 2013. My PhD thesis focused on the reduction of normal tissue damage and improvement of radiation therapy efficacy through the study of specific immunoregulatory molecules and inflammatory cells.
With my main scientific interests being cancer and immunology, I wished to continue research on a project that could directly translate research in a clinical setting. Thus, I joined the prostate cancer vaccine program at the Jenner Institute in September 2013.
Despite the significant advances in the field of immunotherapy as an alternative, or combination treatment of cancer patients, benefits of vaccination still remain low. With the main focus on prostate tumour immunology and immunotherapy, most of my work is based on testing the immunogenicity and protective efficacy of heterologous vaccination strategies on prostate cancer models. The aim of these pre-clinical studies is not only to assess tumour protection targeting a range of well-known prostate cancer antigens, but also to identify new tumour specific antigens and validate them as targets for an effective prostate cancer vaccine.
Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016 Jun;65(6):701-13.
Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget. 2017 May 7.